Details
Stereochemistry | UNKNOWN |
Molecular Formula | C17H28N2O |
Molecular Weight | 276.417 |
Optical Activity | ( - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCN(CC)C(CC)C(=O)NC1=C(C)C=CC=C1C
InChI
InChIKey=VTUSIVBDOCDNHS-UHFFFAOYSA-N
InChI=1S/C17H28N2O/c1-6-12-19(8-3)15(7-2)17(20)18-16-13(4)10-9-11-14(16)5/h9-11,15H,6-8,12H2,1-5H3,(H,18,20)
Molecular Formula | C17H28N2O |
Molecular Weight | 276.417 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
DescriptionSources: http://www.rxlist.com/duranest-drug.htmCurator's Comment: description was created based on several sources, including
http://www.kiessig.com/drugs/druginfo.aspx?id=1218 | http://www.kiessig.com/drugs/druginfo.aspx?id=1218 | https://www.ncbi.nlm.nih.gov/pubmed/8799190 | https://www.ncbi.nlm.nih.gov/pubmed/8085162
Sources: http://www.rxlist.com/duranest-drug.htm
Curator's Comment: description was created based on several sources, including
http://www.kiessig.com/drugs/druginfo.aspx?id=1218 | http://www.kiessig.com/drugs/druginfo.aspx?id=1218 | https://www.ncbi.nlm.nih.gov/pubmed/8799190 | https://www.ncbi.nlm.nih.gov/pubmed/8085162
Etidocaine, marketed under the trade name Duranest, is a local anesthetic given by injection during surgical procedures and labor and delivery. Etidocaine has a long duration of activity, and the main disadvantage of using during dentistry is increased bleeding during surgery. Etidocaine stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthetic action.
CNS Activity
Sources: http://www.kiessig.com/drugs/druginfo.aspx?id=1218
Curator's Comment: http://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC2163529&blobtype=pdf
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL4187 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8085162 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | DURANEST Approved UseINDICATIONS AND USAGE. Duranest (Etidocaine HCl) Injections are indicated for infiltration anesthesia, peripheral nerve blocks (e.g., brachial plexus, intercostal, retrobulbar, ulnar, inferior alveolar), and central neural block (i.e., lumbar or caudal epidural blocks). Launch Date1976 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
12.5 μg/mL |
20 mL single, peridural dose: 20 mL route of administration: Peridural experiment type: SINGLE co-administered: EPINEPHRINE |
ETIDOCAINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1.8 μg × h/mL |
20 mL single, peridural dose: 20 mL route of administration: Peridural experiment type: SINGLE co-administered: EPINEPHRINE |
ETIDOCAINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2.7 h |
20 mL single, peridural dose: 20 mL route of administration: Peridural experiment type: SINGLE co-administered: EPINEPHRINE |
ETIDOCAINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
6% |
20 mL single, peridural dose: 20 mL route of administration: Peridural experiment type: SINGLE co-administered: EPINEPHRINE |
ETIDOCAINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
PubMed
Title | Date | PubMed |
---|---|---|
Toxic systemic reactions of bupivacaine and etidocaine. | 1995 Jan |
|
Benefit and risks of local anesthetics in infants and children. | 2002 |
|
Block of voltage-operated sodium channels by 2,6-dimethylphenol, a structural analogue of lidocaine's aromatic tail. | 2002 Sep |
|
Complications and controversies of regional anaesthesia: a review. | 2009 Oct |
|
Direct vasocontractile activities of bupivacaine enantiomers on the isolated rat thoracic aorta. | 2010 |
|
The effects of volatile induction and maintenance of anesthesia and selective spinal anesthesia on QT interval, QT dispersion, and arrhythmia incidence. | 2010 Jun |
|
Intravenous lipid emulsion in clinical toxicology. | 2010 Oct 5 |
|
Circadian effects on neural blockade of intrathecal hyperbaric bupivacaine. | 2010 Sep |
Patents
Sample Use Guides
The maximum dose to be employed as a single injection should be determined on the basis of the status of the patient and the type of regional anesthetic technique to be performed. Although single injections of 450 mg have been employed for regional anesthesia without adverse effects, at present it is strongly recommended that the maximal dose as a single injection should not exceed 400 mg (approximately 8.0 mg/kg or 3.6 mg/lb based on a 50 kg person) with epinephrine 1:200,000 and 300 mg (approximately 6 mg/kg or 2.7 mg/lb based on a 50 kg person) without epinephrine.
Route of Administration:
Intramuscular
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/80851
Rat brain type IIA Na+ channels expressed in Xenopus oocytes were stimulated infrequently (1 pulse per 20 s, all currents were elicited by 15-ms pulses to 0 mV.) This tonic block mainly reflects drug binding to resting channels, the channel state that predominated at the holding potential of -90 mV. Etidocaine (200 mkM) decrease activities of WT Type IIA Na+ channels on ~40%.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:13:09 GMT 2023
by
admin
on
Sat Dec 16 11:13:09 GMT 2023
|
Record UNII |
K9D2CE52PU
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
K9D2CE52PU
Created by
admin on Sat Dec 16 11:13:09 GMT 2023 , Edited by admin on Sat Dec 16 11:13:09 GMT 2023
|
PRIMARY | |||
|
38188-41-9
Created by
admin on Sat Dec 16 11:13:09 GMT 2023 , Edited by admin on Sat Dec 16 11:13:09 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
RACEMATE -> ENANTIOMER |